Amid an ongoing shortage of nirsevimab, an RSV immunization for young children, the U.S. Centers for Disease Control and Prevention has announced that more than 77,000 additional doses will be distributed "immediately."
These doses will be going to doctor's offices and hospitals through the CDC's Vaccines for Children Program and commercial channels, according to Thursday's announcement.
Nirsevimab, marketed as Beyfortus, is a long-acting monoclonal antibody administered as an injection to protect infants against severe illness from respiratory syncytial virus or RSV infections, which are the leading cause of hospitalization in infants.
"Helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young children, families and the health care system remains a priority," Dr. Patrizia Cavazzoni, director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, said in the announcement. "We will continue to use all our regulatory tools to help bring safe, effective and high-quality medicines to the public."... Read More: WBAL TV